RPTX Repare Therapeutics Inc.

Nasdaq reparerx.com


$ 1.76 $ 0.00 (0 %)    

Thursday, 30-Oct-2025 15:00:30 EDT
QQQ $ 626.33 $ -5.69 (-0.9 %)
DIA $ 474.96 $ 0.81 (0.17 %)
SPY $ 680.06 $ -3.78 (-0.55 %)
TLT $ 90.57 $ 0.17 (0.19 %)
GLD $ 369.88 $ 4.77 (1.32 %)
$ 1.78
$ 1.76
$ 1.75 x 100
$ 1.78 x 100
$ 1.73 - $ 1.77
$ 0.89 - $ 4.07
151,125
na
76.47M
$ 1.01
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-03-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-04-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-repare-therapeutics-lowers-price-target-to-3

HC Wainwright & Co. analyst Robert Burns maintains Repare Therapeutics (NASDAQ:RPTX) with a Buy and lowers the price tar...

 hc-wainwright--co-maintains-buy-on-repare-therapeutics-lowers-price-target-to-3

HC Wainwright & Co. analyst Robert Burns maintains Repare Therapeutics (NASDAQ:RPTX) with a Buy and lowers the price tar...

 repare-therapeutics-to-share-initial-topline-safety-tolerability-and-early-efficacy-data-from-phase-1-lions-trial-in-poster-presentation-at-aacr-nci-eortc-international-conference-2025

Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company...

 repare-therapeutics-q1-eps-071-misses-066-estimate

Repare Therapeutics (NASDAQ:RPTX) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of...

 repare-therapeutics-out-licenses-its-discovery-platforms-to-dcx-biotherapeutics-will-receive-4m-upfront-and-999-common-equity-position-in-dcx-and-is-eligible-for-milestone-payments-and-royalties

Under the terms of the out-licensing agreement, Repare will receive upfront and near-term payments totaling $4 million, as well...

 cathie-woods-ark-invest-offloads-uipath-prime-medicine-and-repare-therapeutics

On April 11th, 2025, Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable ...

 cathie-wood-doubles-down-mops-up-another-139-million-worth-of-robinhood-stock-amid-trump-tariff-dip

On Thursday, April 3, 2025, Cathie Wood-led Ark Invest purchased Robinhood stock worth $1.39 million amid a broader market slump.

 repare-therapeutics-names-steve-forte-as-president-and-ceo-effective-april-11-2025-lloyd-m-segal-resigns

He will serve in this new role in addition to his current role as the Company's Chief Financial Officer.Additionally, Sandr...

 cathie-woods-ark-invest-loads-up-on-robinhood-nvidia-backed-coreweave-offloads-spotify-roku

Cathie Wood-led Ark Invest made substantial trades, buying Robinhood and CoreWeave shares and selling Roblox, Genius Sports, Ro...

 cathie-woods-ark-invest-scoops-up-iridium-beam-pacific-biosciences-while-offloading-illumina-and-amgen

Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV.

 cathie-woods-ark-invest-continues-to-offload-uipath-roblox-loads-up-on-gitlab-ibotta

Ark Invest's Cathie Wood-led funds made significant trades involving GitLab, Intellia, Prime Medicine, UiPath, Ibotta, Robl...

 hc-wainwright--co-maintains-buy-on-repare-therapeutics-lowers-price-target-to-5

HC Wainwright & Co. analyst Robert Burns maintains Repare Therapeutics (NASDAQ:RPTX) with a Buy and lowers the price tar...

 repare-announced-a-re-alignment-of-resources-and-a-re-prioritization-of-its-clinical-portfolio-to-focus-on-rp-1664-and-rp-3467-in-connection-with-the-re-alignment-the-company-is-reducing-its-workforce-by-approximately-75

Exploring partnerships across portfolio, including for Lunre+Camo

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION